Literature DB >> 10635328

TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.

B R Wong1, D Besser, N Kim, J R Arron, M Vologodskaia, H Hanafusa, Y Choi.   

Abstract

TRANCE, a TNF family member, and its receptor, TRANCE-R, are critical regulators of dendritic cell and osteoclast function. Here, we demonstrate that TRANCE activates the antiapoptotic serine/threonine kinase Akt/PKB through a signaling complex involving c-Src and TRAF6. A deficiency in c-Src or addition of Src family kinase inhibitors blocks TRANCE-mediated PKB activation in osteoclasts. c-Src and TRAF6 interact with each other and with TRANCE-R upon receptor engagement. TRAF6, in turn, enhances the kinase activity of c-Src leading to tyrosine phosphorylation of downstream signaling molecules such as c-Cbl. These results define a mechanism by which TRANCE activates Src family kinases and PKB and provide evidence of cross-talk between TRAF proteins and Src family kinases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10635328     DOI: 10.1016/s1097-2765(00)80232-4

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  156 in total

1.  RANKing the importance of measles virus in Paget's disease.

Authors:  F P Ross
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

3.  Neurotrophins regulate Schwann cell migration by activating divergent signaling pathways dependent on Rho GTPases.

Authors:  Junji Yamauchi; Jonah R Chan; Eric M Shooter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

4.  Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members.

Authors:  Duorong Xu; Zhenqi Shi; Jay McDonald; George Pan; Xuemei Cao; Xueqing Yu; Xu Feng
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

Review 5.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

Review 6.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

7.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

8.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo.

Authors:  Hyun-Ju Kim; Kaihua Zhang; Lihong Zhang; F Patrick Ross; Steven L Teitelbaum; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.